Nanobiotix S.A.
36.64USD
-1.5500 (-4.06%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current year | $-0.13▼ | $-0.11 | 0 | 0 |
| Next year | $-0.29▼ | $0.2 | 0 | 0 |
8 ratings from 4 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Leerink Partners | Maintained | Outperform | $37 $46 | Jun 4, 2026 |
| UBS | Maintained | Neutral | $3.5 $30 | May 1, 2026 |
| Guggenheim | Maintained | Buy | $26 $36 | Apr 2, 2026 |
| Guggenheim | Maintained | Buy | $8 $26 | Feb 6, 2026 |
| Guggenheim | Maintained | Buy | $12 $8 | Apr 4, 2025 |
| Guggenheim | Initiated | Buy | $12 | Aug 28, 2024 |
| Leerink Partners | Initiated | Outperform | $11 | Dec 8, 2023 |
| Evercore ISI Group | Initiated | Outperform | — | Jan 6, 2021 |
No analyst notes on NBTX yet.
Analyst Ratings
3 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 4 | 1 | 0 | 0 | Buy2.20 |
| 1 mo ago | 0 | 6 | 1 | 0 | 0 | Buy2.14 |